Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis – efficacy findings up to week 12
By
- AMS
posted
Apr 17, 2020 09:54 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events
- AMS
Added Apr 22, 2020
Blog Entry
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
- AMS
Added Aug 05, 2021
Blog Entry
An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan
- AMS
Added Apr 17, 2020
Blog Entry
Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany
- AMS
Added Jul 27, 2020
Blog Entry
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis
- AMS
Added Mar 18, 2021
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic